FAKTOR-OPTIONSSCHEIN - NOVO-NORDISK B | Real-time Boerse Frankfurt Warrants 08:23:49 14/05/2024 pm IST | ||
| 9.55 EUR | +5.76% |
|
| Current month | -11.99% | ||
| 1 month | -26.04% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
NOVO NORDISK A/S
| Date | Price | Change |
|---|---|---|
| 14/24/14 | 9.55 | +5.76% |
| 13/24/13 | 9.03 | -13.09% |
| 10/24/10 | 10.39 | +0.48% |
| 09/24/09 | 10.34 | -6.09% |
| 08/24/08 | 11.01 | +3.57% |
Real-time Boerse Frankfurt Warrants
Last update May 14, 2024 at 08:23 pm IST
More quotesStatic data
| Product type | Exotic Products |
|---|---|
| Buy / Sell | CALL |
| Underlying | NOVO NORDISK A/S |
| Issuer | 
Société Générale
|
| WKN | SW7Q5T |
| ISIN | DE000SW7Q5T4 |
| Date issued | 15/03/2024 |
| Strike | 908 kr |
| Maturity | Unlimited |
| Parity | 1 : 1 |
| Emission price | 10.19 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 14.6 € |
|---|---|
| Lowest since issue | 8.62 € |
| Spread | 0.03 € |
| Spread % | 0.32% |
Company Profile
Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- diabetes and obesity treatment products (92.6%);
- rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc.
Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
Sector
-
Consensus: Novo Nordisk A/S
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
25
Last Close Price
909.9
DKK
Average target price
909.2
DKK
Spread / Average Target
-0.07%
- Stock Market
- Certificates
- Certificat